3
0
Wells Fargo upgraded GoodRx Holdings Inc (NASDAQ:GDRX), noting 2024 guidance has good visibility with upside potential to both estimates & valuation multiples.
Wells Fargo analyst anticipates that GoodRx’s EBITDA margins could surpass expectations in 2025, suggesting a favorable outlook for the company.
Despite potential challenges from strategic shifts in the past two years, such as initiatives to enhance member retention and partnerships with pharmacy benefit managers, there are signs of improved revenue visibility and reduced downside risk.
Wells Fargo upgraded GoodRx from Equal Weight to Overweight, with a price target of $10, up from $7.50.
In February, GoodRx reported fourth-quarter FY23 results …
Full story available on Benzinga.com
Visited 3 times, 1 visit(s) today